Tunable antibody-drug conjugate tested in ovarian cancer model
Sep. 12, 2024
OS Therapies Inc. has announced promising data in animal models of ovarian cancer for its first therapeutic candidate developed based upon its proprietary tunable antibody-drug conjugate (tADC) platform.